CLYM vs DMAC: stock comparison and AI forecast
Climb Bio, Inc. (CLYM) and Diamedica Therapeutics Inc. (DMAC) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CLYM Climb Bio, Inc.
- Market Cap
- $509M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
DMAC Diamedica Therapeutics Inc.
- Price
- $9.04 +38.4% · 6M
- Market Cap
- $487M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- CLYM and DMAC have similar market capitalizations ($509M and $487M).
- DMAC carries 0.17 times debt per unit of equity, against 0.04 times for CLYM.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CLYM | DMAC |
|---|---|---|
| Market Cap | $509M | $487M |
| P/B Ratio | 2.23x | 12.72x |
| EPS | $-0.87 | – |
| Book Value/Share | $3.97 | $0.71 |
| FCF/Share | – | $-0.58 |
Profitability & Margins
| Metric | CLYM | DMAC |
|---|---|---|
| ROE | -26.0% | -97.9% |
| ROA | -25.1% | -83.4% |
| ROIC | -29.2% | -102.1% |
| Tax Rate | 0.0% | -0.1% |
Financial Health
| Metric | CLYM | DMAC |
|---|---|---|
| Current Ratio | 26.58x | 6.72x |
| D/E Ratio | 0.04x | 0.17x |
| Financial Leverage | 1.04x | 1.17x |
| Interest Coverage | – | -2134.0x |
| Working Capital | $202M | $38M |
Cash Flow
| Metric | CLYM | DMAC |
|---|---|---|
| Operating Cash Flow | -$53M | -$32M |
| Free Cash Flow | – | -$32M |
| Capital Spending | – | -$30K |
Income Statement
| Metric | CLYM | DMAC |
|---|---|---|
| Operating Income | -$67M | -$39M |
| Net Income | -$59M | -$38M |
| R&D Expense | $44M | $29M |
Dividend & Shareholder Information
| Metric | CLYM | DMAC |
|---|---|---|
| Shares Outstanding | 57M | 54M |
| EPS Growth | -495.4% | – |
CLYM vs DMAC: stock comparison and AI forecast
Which is bigger, CLYM or DMAC?
CLYM and DMAC have similar market capitalizations ($509M and $487M).
Which one does Intratio's AI model rank higher, CLYM or DMAC?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.